Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.78 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PLK4 | O00444 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | PAK4 | O96013 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | LTK | P29376 | 1/20 | 0.38 |
| ▸ | GRK5 | P34947 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5455999 | 0.88 | USP2 (0.92) | USP2HPGDHTTLMNANPSR1 | |
| SCHEMBL3578599 | 0.88 | USP2 (0.92) | USP2HPGDHTTLMNANPSR1 | |
| SCHEMBL3578601 | 0.88 | USP2 (0.92) | USP2HPGDHTTLMNANPSR1 | |
| SCHEMBL9039199 | 0.72 | USP2 (0.53) | USP2HPGDHTTLMNANPSR1 | |
| SCHEMBL9039193 | 0.72 | USP2 (0.53) | USP2HPGDHTTLMNANPSR1 | |
| SCHEMBL17225406 | 0.69 | NOS2 (0.45) | USP2LMNANOS2PLK4CHEK1 | |
| SCHEMBL7934124 | 0.68 | USP2 (0.48) | USP2HPGDHTTLMNANPSR1 | |
| SCHEMBL7293034 | 0.68 | USP2 (0.48) | USP2HPGDHTTLMNANPSR1 | |
| SCHEMBL15219995 | 0.67 | CES1 (0.50) | USP2HPGDLMNANOS2PLK4 | |
| SCHEMBL9865315 | 0.64 | USP2 (0.44) | USP2HPGDNOS2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401830-A2 | QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | WARNER-LAMBERT COMPANY | 2003-06-19 | — | — | US | disclosed |
| WO-2002102793-A2 | QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-12-27 | — | — | WO | disclosed |
| WO-2001015677-A2 | USE OF 5-HT1B/1D AGONISTS TO TREAT OTIC PAIN | ALCON LABORATORIES, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| US-5252749-A | Binding to serotonin receptors 5HT3, 5HT1D and 5HT1B; hypotensive agents; cardiovascular and psychological disorders | ELF SANOFI (FR) | 1993-10-12 | — | — | US | disclosed |
| US-5252749-A | Binding to serotonin receptors 5HT3, 5HT1D and 5HT1B; hypotensive agents; cardiovascular and psychological disorders | ELF SANOFI (FR) | 1993-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | ABCC1, RPS6KA1, SIGMAR1 | USP2 4179/4885HPGD 633/4885HTT 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.